60 is the total number of securities Foresite Capital Management II, LLC has owned. The longest Foresite Capital Management II, LLC has owned a single stock is 29 quarters.
| Period | Weighting | Quarter | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
| EPZM | Epizyme, Inc. | 29 | 29 | 0.66% | 5.79% | 11.92% | Q4 2014 | Q4 2021 | 29 |
| XLRN | Acceleron Pharma Inc. | 17 | 2 | 0.23% | 2.23% | 4.84% | Q2 2015 | Q3 2021 | 24 |
| AERI | Aerie Pharmaceuticals,... | 22 | 22 | 0.80% | 20.40% | 40.27% | Q4 2014 | Q1 2020 | 22 |
| TXG | 10x Genomics, Inc. | 17 | 17 | 72.85% | 95.06% | 100.00% | Q3 2019 | Q3 2023 | 17 |
| AIMT | Aimmune Therapeutics, ... | 17 | 17 | 11.53% | 32.00% | 40.96% | Q3 2015 | Q3 2019 | 17 |
| ALDR | Alder BioPharmaceutica... | 16 | 16 | 0.58% | 7.71% | 12.56% | Q4 2015 | Q3 2019 | 16 |
| ZFGN | Zafgen, Inc. | 12 | 12 | 0.04% | 6.34% | 33.47% | Q4 2014 | Q3 2017 | 12 |
| BDSI | BioDelivery Sciences I... | 8 | 4 | 0.03% | 1.44% | 3.24% | Q4 2014 | Q1 2019 | 12 |
| INSM | Insmed Incorporated | 11 | 11 | 0.88% | 6.57% | 13.75% | Q3 2017 | Q1 2020 | 11 |
| ADAP | Adaptimmune Therapeuti... | 5 | 4 | 1.49% | 5.20% | 11.30% | Q2 2015 | Q4 2018 | 9 |
| NSTG | NanoString Technologie... | 9 | 9 | 1.92% | 4.36% | 7.60% | Q2 2015 | Q2 2017 | 9 |
| NVET | Nexvet Biopharma publi... | 9 | 9 | 0.78% | 1.73% | 3.37% | Q1 2015 | Q1 2017 | 9 |
| OREX | Orexigen Therapeutics,... | 8 | 8 | 0.86% | 6.75% | 19.48% | Q4 2014 | Q3 2016 | 8 |
| UAM | Universal American Corp. | 6 | 1 | 5.85% | 10.89% | 19.06% | Q4 2014 | Q3 2016 | 7 |
| SCYX | SCYNEXIS, Inc. | 6 | 6 | 0.66% | 1.97% | 4.53% | Q4 2014 | Q1 2016 | 6 |
| RGLS | Regulus Therapeutics Inc. | 5 | 5 | 3.44% | 4.65% | 6.92% | Q1 2015 | Q1 2016 | 5 |
| NVAX | Novavax, Inc. | 5 | 5 | 1.59% | 3.04% | 4.96% | Q3 2020 | Q3 2021 | 5 |
| JUNO | Juno Therapeutics, Inc. | 3 | 2 | 1.36% | 2.25% | 3.29% | Q4 2014 | Q4 2017 | 5 |
| QTNT | Quotient Limited | 5 | 5 | 1.03% | 2.21% | 4.04% | Q4 2014 | Q4 2015 | 5 |
| ARDX | Ardelyx, Inc. | 3 | 1 | 0.09% | 1.52% | 2.91% | Q4 2015 | Q1 2018 | 5 |
| RGNX | REGENXBIO Inc. | 4 | 1 | 0.36% | 0.79% | 1.05% | Q3 2015 | Q1 2020 | 5 |
| NeuroDerm Ltd. | 5 | 5 | 0.32% | 0.59% | 0.92% | Q2 2015 | Q2 2016 | 5 | |
| SGMO | Sangamo Therapeutics, ... | 3 | 1 | 0.19% | 0.58% | 1.53% | Q1 2015 | Q3 2018 | 5 |
| ADRO | Aduro Biotech, Inc. | 4 | 4 | 8.29% | 14.68% | 22.42% | Q2 2015 | Q1 2016 | 4 |
| Alder Biopharmaceutica... | 4 | 4 | 2.69% | 4.35% | 6.41% | Q4 2014 | Q3 2015 | 4 | |
| DNLI | Denali Therapeutics Inc. | 4 | 4 | 1.23% | 1.49% | 2.01% | Q4 2017 | Q3 2018 | 4 |
| OREXQ | Orexigen Therapeutics,... | 4 | 4 | 0.45% | 0.66% | 0.92% | Q4 2016 | Q3 2017 | 4 |
| BDSI | BioDelivery Sciences I... | 3 | 1 | 0.34% | 0.54% | 0.82% | Q4 2014 | Q1 2016 | 4 |
| DERM | Dermira, Inc. | 3 | 3 | 0.64% | 1.72% | 2.71% | Q1 2017 | Q3 2017 | 3 |
| AGRX | Agile Therapeutics, Inc. | 3 | 3 | 0.15% | 1.64% | 2.52% | Q4 2014 | Q2 2015 | 3 |
| TWST | Twist Bioscience Corpo... | 3 | 3 | 0.76% | 0.95% | 1.19% | Q4 2018 | Q2 2019 | 3 |
| JNCE | Jounce Therapeutics, Inc. | 3 | 3 | 0.76% | 0.89% | 1.13% | Q1 2017 | Q3 2017 | 3 |
| BDSI | BioDelivery Sciences I... | 2 | 1 | 0.50% | 0.81% | 1.40% | Q4 2014 | Q4 2015 | 3 |
| OREX | Orexigen Therapeutics,... | 2 | 1 | 0.05% | 0.44% | 1.04% | Q4 2014 | Q3 2015 | 3 |
| AXGT | Axovant Sciences Ltd. | 3 | 3 | 0.26% | 0.37% | 0.46% | Q2 2015 | Q4 2015 | 3 |
| ASPX | Auspex Pharmaceuticals... | 2 | 2 | 4.46% | 5.32% | 6.17% | Q4 2014 | Q1 2015 | 2 |
| Ardelyx, Inc. | 2 | 2 | 2.71% | 2.81% | 2.90% | Q2 2015 | Q3 2015 | 2 | |
| TTOO | T2 Biosystems, Inc. | 2 | 2 | 2.14% | 2.58% | 3.01% | Q4 2014 | Q1 2015 | 2 |
| RXDX | Ignyta, Inc. | 2 | 2 | 1.09% | 1.19% | 1.29% | Q4 2014 | Q1 2015 | 2 |
| ANAC | Anacor Pharmaceuticals... | 2 | 2 | 0.98% | 1.08% | 1.17% | Q4 2015 | Q1 2016 | 2 |
| BITI | Biotie Therapies Corp. | 2 | 2 | 0.32% | 0.82% | 1.32% | Q2 2015 | Q3 2015 | 2 |
| LOXO | Loxo Oncology, Inc. | 2 | 2 | 0.35% | 0.44% | 0.53% | Q3 2017 | Q4 2017 | 2 |
| BLCM | Bellicum Pharmaceutica... | 2 | 2 | 0.27% | 0.41% | 0.56% | Q1 2017 | Q2 2017 | 2 |
| NTRA | Natera, Inc. | 1 | 1 | 0.19% | 0.35% | 0.51% | Q1 2017 | Q4 2018 | 2 |
| Aimmune Therapeutics, ... | 1 | 1 | 4.62% | 4.62% | 4.62% | Q1 2018 | Q1 2018 | 1 | |
| SAGE | Sage Therapeutics, Inc. | 1 | 1 | 3.62% | 3.62% | 3.62% | Q4 2014 | Q4 2014 | 1 |
| PRQR | ProQR Therapeutics N.V. | 1 | 1 | 2.57% | 2.57% | 2.57% | Q4 2014 | Q4 2014 | 1 |
| Anacor Pharmaceuticals... | 1 | 1 | 2.36% | 2.36% | 2.36% | Q4 2014 | Q4 2014 | 1 | |
| Bellicum Pharmaceutica... | 1 | 1 | 1.66% | 1.66% | 1.66% | Q4 2014 | Q4 2014 | 1 | |
| ANAC | Anacor Pharmaceuticals... | 1 | 1 | 1.17% | 1.17% | 1.17% | Q4 2015 | Q4 2015 | 1 |
| Anacor Pharmaceuticals... | 1 | 1 | 1.11% | 1.11% | 1.11% | Q3 2015 | Q3 2015 | 1 | |
| Anacor Pharmaceuticals... | 1 | 1 | 1.11% | 1.11% | 1.11% | Q3 2015 | Q3 2015 | 1 | |
| QURE | uniQure N.V. | 1 | 1 | 0.75% | 0.75% | 0.75% | Q4 2017 | Q4 2017 | 1 |
| EPZM | Epizyme, Inc. | 1 | 1 | 0.59% | 0.59% | 0.59% | Q3 2015 | Q3 2015 | 1 |
| RGLS | Regulus Therapeutics Inc. | 1 | 1 | 0.50% | 0.50% | 0.50% | Q3 2015 | Q3 2015 | 1 |
| RGLS | Regulus Therapeutics Inc. | 1 | 1 | 0.50% | 0.50% | 0.50% | Q3 2015 | Q3 2015 | 1 |
| OREX | Orexigen Therapeutics,... | 1 | 1 | 0.42% | 0.42% | 0.42% | Q4 2014 | Q4 2014 | 1 |
| AKBA | Akebia Therapeutics Inc. | 1 | 1 | 0.33% | 0.33% | 0.33% | Q2 2017 | Q2 2017 | 1 |
| Amedica Corporation | 1 | 1 | 0.12% | 0.12% | 0.12% | Q4 2014 | Q4 2014 | 1 | |
| Alder BioPharmaceutica... | 1 | 1 | 0.01% | 0.01% | 0.01% | Q4 2017 | Q4 2017 | 1 | |
Download | |||||||||
The securities at the top of the list , including Epizyme, Inc., Acceleron Pharma Inc., and Aerie Pharmaceuticals, Inc., are the highest-conviction holdings of Foresite Capital Management II, LLC.
The conviction is calculated by counting the number of quarters a security has been reported by Foresite Capital Management II, LLC. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Foresite Capital Management II, LLC owns currently or has owned in the past.